<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29522439</article-id><article-id pub-id-type="pmc">5872747</article-id><article-id pub-id-type="doi">10.3390/nu10030329</article-id><article-id pub-id-type="publisher-id">nutrients-10-00329</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Resveratrol in Patients with Minimal Hepatic Encephalopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3655-4307</contrib-id><name><surname>Malaguarnera</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00329">1</xref><xref ref-type="aff" rid="af2-nutrients-10-00329">2</xref><xref rid="c1-nutrients-10-00329" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3655-4307</contrib-id><name><surname>Pennisi</surname><given-names>Manuela</given-names></name><xref ref-type="aff" rid="af3-nutrients-10-00329">3</xref></contrib><contrib contrib-type="author"><name><surname>Bertino</surname><given-names>Gaetano</given-names></name><xref ref-type="aff" rid="af4-nutrients-10-00329">4</xref></contrib><contrib contrib-type="author"><name><surname>Motta</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="af3-nutrients-10-00329">3</xref><xref ref-type="aff" rid="af4-nutrients-10-00329">4</xref></contrib><contrib contrib-type="author"><name><surname>Borz&#x000ec;</surname><given-names>Antonio Maria</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00329">1</xref></contrib><contrib contrib-type="author"><name><surname>Vicari</surname><given-names>Enzo</given-names></name><xref ref-type="aff" rid="af4-nutrients-10-00329">4</xref></contrib><contrib contrib-type="author"><name><surname>Bella</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="af5-nutrients-10-00329">5</xref></contrib><contrib contrib-type="author"><name><surname>Drago</surname><given-names>Filippo</given-names></name><xref ref-type="aff" rid="af2-nutrients-10-00329">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7145-6377</contrib-id><name><surname>Malaguarnera</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00329">1</xref><xref ref-type="aff" rid="af2-nutrients-10-00329">2</xref></contrib></contrib-group><aff id="af1-nutrients-10-00329"><label>1</label>Research Center &#x0201c;The Great Senescence&#x0201d;, University of Catania, 95126 Catania, Italy; <email>antoniomaria.borzi@gmail.com</email> (A.M.B.); <email>michele.malaguarnera@gmail.com</email> (M.M.)</aff><aff id="af2-nutrients-10-00329"><label>2</label>Department of Biomedical and Biotechnological Science, University of Catania, 95123 Catania, Italy; <email>f.drago@unict.it</email></aff><aff id="af3-nutrients-10-00329"><label>3</label>Spinal Unit of Cannizzaro Hospital, University of Catania, 95100 Catania, Italy; <email>manuelapennisi78@gmail.com</email> (M.P.); <email>mottam@unict.it</email> (M.M.)</aff><aff id="af4-nutrients-10-00329"><label>4</label>Department of Experimental and Clinical Medicine, University of Catania, 95123 Catania, Italy; <email>gaetanobertinounict@gmail.com</email> (G.B.); <email>enzodante@email.it</email> (E.V.)</aff><aff id="af5-nutrients-10-00329"><label>5</label>Department &#x0201c;G.F. Ingrassia&#x0201d;, Section of Neurosciences, University of Catania, 95123 Catania, Italy; <email>rbella@unict.it</email></aff><author-notes><corresp id="c1-nutrients-10-00329"><label>*</label>Correspondence: <email>giulia.malaguarnera@live.it</email>; Tel.: +39-09-57262008; Fax: +39-09-57262011</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>10</volume><issue>3</issue><elocation-id>329</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>07</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: Minimal Hepatic Encephalopathy (MHE) is characterized by an impairment of social interaction, emotional behavior, sleep disorders, physical and mental symptoms, and diminished Quality of Life (QoL). The aim of our study is evaluating the potential liver health promoting a perspective of Resveratrol (RV) activities and evaluate whether RV treatment may improve health related quality of life (HRQL) and reduce depression and anxiety in patients with MHE. Methods: <italic>W</italic>e evaluated depression using the Beck Depression Inventory test, anxiety with State-trait anxiety inventory test, quality of life through SF-36 test, and ammonia serum levels in 70 MHE patients that were randomized into two groups. Results: In the comparison between RV group and placebo group we observed a decrease in Back Depression Inventory (BDI) (<italic>p</italic> &#x0003c; 0.001), in State-trait anxiety inventory (STAI) (<italic>p</italic> &#x0003c; 0.001), and improve in physical function (<italic>p</italic> &#x0003c; 0.001), in role physical (<italic>p</italic> &#x0003c; 0.05), in body pain (<italic>p</italic> &#x0003c; 0.05), in general health (<italic>p</italic> &#x0003c; 0.001), in vitality (<italic>p</italic> &#x0003c; 0.05), and in social function (<italic>p</italic> &#x0003c; 0.001). Conclusions: Resveratrol showed efficacy in the treatment of depression, anxiety, and ammonia serum levels, and improved the quality of life Of MHE patients.</p></abstract><kwd-group><kwd>depression</kwd><kwd>anxiety</kwd><kwd>resveratrol</kwd><kwd>ammonia</kwd><kwd>quality of life</kwd><kwd>minimal hepatic encephalopathy</kwd></kwd-group></article-meta></front><body><sec id="sec1-nutrients-10-00329"><title>1. Introduction</title><p>Minimal Hepatic Encephalopathy (MHE) is a frequent and common complication of cirrhosis, affecting nearly 80% of cirrhotic patients. Physical examination in MHE is often normal; patients may present subtle abnormalieties, interfering with executive function, including their working memory and orientation, impairment of social interaction, emotional behavior, sleep disorders, physical and mental symptoms, and diminished Quality of Life (QoL) [<xref rid="B1-nutrients-10-00329" ref-type="bibr">1</xref>].</p><p>This underrecognized and underdiagnosized syndrome often presents minimal changes in personality and in memory, intellectual function, concentration, and coordination.</p><p>These disorders impinge on the health related quality of life and have a negative prognostic value in relation to the occurrence of both bouts of overt hepatic encephalopathy and death [<xref rid="B2-nutrients-10-00329" ref-type="bibr">2</xref>].</p><p>Resveratrol (RV) is a natural phytoalexin, which is isolated from the roots of with hellebore (Veratrum grandiflorum Hoes). RV is present in two isoforms, cis/trans, and trans isomer is the biologically active one. It has been report that RV plays role as antinflammatory, antioxidants, antiviral, and exerts anticancer activities through many different mechanisms [<xref rid="B3-nutrients-10-00329" ref-type="bibr">3</xref>,<xref rid="B4-nutrients-10-00329" ref-type="bibr">4</xref>,<xref rid="B5-nutrients-10-00329" ref-type="bibr">5</xref>,<xref rid="B6-nutrients-10-00329" ref-type="bibr">6</xref>,<xref rid="B7-nutrients-10-00329" ref-type="bibr">7</xref>,<xref rid="B8-nutrients-10-00329" ref-type="bibr">8</xref>,<xref rid="B9-nutrients-10-00329" ref-type="bibr">9</xref>,<xref rid="B10-nutrients-10-00329" ref-type="bibr">10</xref>,<xref rid="B11-nutrients-10-00329" ref-type="bibr">11</xref>].</p><p>RV showed protective effect against neuro-inflammation inhibiting reactive oxygen species (ROS) production and mitogen-activated protein kinases (MAPK) signal transduction pathways, and also inactivating signalling pathways of both nuclear factor-kappa b (NF-&#x003ba;B) and silent mating type information regulation 2 homolog 1 (SIRT1) [<xref rid="B12-nutrients-10-00329" ref-type="bibr">12</xref>,<xref rid="B13-nutrients-10-00329" ref-type="bibr">13</xref>]. SIRT belongs to a protein family consisting of seven individual members, which are involved in cellular metabolism, mitochondrial function, and stress responses modulation [<xref rid="B14-nutrients-10-00329" ref-type="bibr">14</xref>].</p><p>The RV attracted the interest of researchers for the combined antidepressant and anti-inflammatory effects [<xref rid="B11-nutrients-10-00329" ref-type="bibr">11</xref>].</p><p>The aim of the current study was the evaluation of RV in liver health, in health related quality of life (HRQL), and in reduction of depression and anxiety in patients with MHE.</p></sec><sec id="sec2-nutrients-10-00329"><title>2. Patients and Methods</title><sec id="sec2dot1-nutrients-10-00329"><title>2.1. Study Design</title><p>Seventy-five patients with cirrhosis and minimal cognitive impairment regarding selective attention and executive function were recruited between May 2013 and November 2016 at Cannizzaro Hospital in Catania (Italy).</p><p>The diagnosis of cirrhosis was based on case history, clinical examination, biochemical, endoscopic, and ultrasounds finding; or, when needed, on liver biopsy.</p><p>This observational study was approved by the research ethics committee of Cannizzaro Hospital.</p><p>All of the eligible patients were approached and asked to participate in the study; those who accepted signed the written the informed consent after reading carefully the patients information leaflet.</p><p>75 patients with diagnosis of MHE were enrolled in the study: three withdrew consent, two overt hepatic encephalopathy (<xref ref-type="fig" rid="nutrients-10-00329-f001">Figure 1</xref>). The 70 patients were randomized into two groups, using permuted-block randomization with an allocation ratio 1:1 and block size of four. Random numbers were assigned according to the sequency of their inclusion and patients received respective study products. Group A were treated with RV in pills 19.8 mg, <italic>N</italic>-acetyl cysteine 600 mg, lactoferrin 23.6 g (Resvis Alfa-sigma, Bologna, Italy). Group B were treated with placebo: <italic>N</italic>-acetyl cysteine 600 mg, lactoferrin 23.6 g. The diagnosis of HE was made on the evaluation of consciousness, intellectual behavior, and neuromuscular functions. Mental status was assessed and graded on the basis of West-Haven Criteria [<xref rid="B15-nutrients-10-00329" ref-type="bibr">15</xref>]. The schedule was to receive for 90 days a supply of either RV or placebo. The measurement was made every month, both for efficacy and for tolerability tests.</p></sec><sec id="sec2dot2-nutrients-10-00329"><title>2.2. Protocol</title><p>The inclusion criteria were age 25&#x02013;65 years.</p><p>Cirrhotic patients who performed abnormally on psychometric tests but performed normally on clinical neuropsychiatric examination were diagnosed with MHE. MHE was diagnosed according to guidelines from the final report of the Working Party at the 11th World Congress of Gastroenterology in Vienna in 1998.</p><p>The exclusion criteria were: pregnancy and breast feeding; past history of overt hepatic encephalopathy (OHE); use of interferon or psychoactive drugs, such as benzodiazepines, psychotropic drugs, antiepileptic; alcohol abuse, history of diabetes or renal impairment; significant head injury; arterial hypertension. Patients&#x02019; characteristic included educational status, Child-Turcotte Pugh class, and etiology of cirrhosis [<xref rid="B16-nutrients-10-00329" ref-type="bibr">16</xref>].</p><p>Male patients were considered to have alcohol related cirrhosis if their alcohol intake was more than 50 g and female patients if their intake was more than 30 g for more than five years and if testing showed no viral metabolic or immunologic cause. Chronic hepatitis B and C were diagnosed when testing was positive for the viral markers Hepatitis B surface Antigen (HBsAg) and Hepatitis C virus antibody (anti-HCV) respectively.</p><p>All of the patients underwent to Psychometric Hepatic Encephalopathy Score (PHES) [<xref rid="B17-nutrients-10-00329" ref-type="bibr">17</xref>,<xref rid="B18-nutrients-10-00329" ref-type="bibr">18</xref>], Short Form 36 Health Survey (SF-36) [<xref rid="B19-nutrients-10-00329" ref-type="bibr">19</xref>,<xref rid="B20-nutrients-10-00329" ref-type="bibr">20</xref>,<xref rid="B21-nutrients-10-00329" ref-type="bibr">21</xref>,<xref rid="B22-nutrients-10-00329" ref-type="bibr">22</xref>], Beck Depression Inventory (BDI) [<xref rid="B23-nutrients-10-00329" ref-type="bibr">23</xref>], and State-Trait Anxiety Inventory (STAI) [<xref rid="B22-nutrients-10-00329" ref-type="bibr">22</xref>].</p><sec id="sec2dot2dot1-nutrients-10-00329"><title>2.2.1. Diagnosis of MHE</title><p>The use of neuropsychometric battery tests have been limited to research of minimal HE. We performed the Psycometric Hepatic Encephalopathy Score (PHES), which consists of five psychometric tests that measure psychomotor speed and precision, visual perception, visus-spatial orientation, visual construction, concentration, attention, and memory [<xref rid="B17-nutrients-10-00329" ref-type="bibr">17</xref>,<xref rid="B18-nutrients-10-00329" ref-type="bibr">18</xref>].</p></sec><sec id="sec2dot2dot2-nutrients-10-00329"><title>2.2.2. Neuropsychological Testing</title><sec><title>PHES Test Battery</title><p>PHES Scores a neuropsychological battery composed of five different tests: Number connection test A (NET-A) and B (NET-B), line tracing test, serial dotting test, and digit symbol test [<xref rid="B15-nutrients-10-00329" ref-type="bibr">15</xref>,<xref rid="B16-nutrients-10-00329" ref-type="bibr">16</xref>]. The test detects attention and psychomotor speed, areas that were most affected by HE. PHES score is obtained based on sum of the result of each test [<xref rid="B17-nutrients-10-00329" ref-type="bibr">17</xref>,<xref rid="B18-nutrients-10-00329" ref-type="bibr">18</xref>].</p></sec></sec><sec id="sec2dot2dot3-nutrients-10-00329"><title>2.2.3. SF-36 (Short Form&#x02014;36 Health Survey)</title><p>SF-36 questionnaire measures with eight domain scales and 36 items, health status. [<xref rid="B17-nutrients-10-00329" ref-type="bibr">17</xref>]</p><p>SF-36 provides two summary scores: physical component and mental component and eight health status scales: Physical functioning, role limitation due to physical problems, bodily pain, General health perceptions, vitality, social functioning, role limitation due to emotional problems, and mental health.</p><p>Patients completed the questionnaire and the resulting scores were transformed onto a scale from 0 (the worst possible score) to 100 (the best possible score), as recommended by questionnaires originators [<xref rid="B19-nutrients-10-00329" ref-type="bibr">19</xref>,<xref rid="B20-nutrients-10-00329" ref-type="bibr">20</xref>,<xref rid="B21-nutrients-10-00329" ref-type="bibr">21</xref>,<xref rid="B22-nutrients-10-00329" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot2dot4-nutrients-10-00329"><title>2.2.4. Beck Depression Inventory (BDI)</title><p>BDI is the most widely used instrument for detecting depression. It is a 21-item self report rating inventory that measures characteristic attitudes and symptoms of depression, including mood, sense of failure, pessimism, guilt, punishment, self-dissatisfaction, self dislike, self accusation, crying, suicidal ideas, irritability, social withdrawal, indecisiveness, body image change, and work difficulty. Each answer is scored from 0 to 3. Higher total score indicate more severe depressive symptoms. Index score of &#x02264;9 is considered to be within normal range, a score of 10&#x02013;15 shows minimal depressive symptomatology, a score of 16&#x02013;31 points toward mild depression, a score of 32&#x02013;47 is in favor of moderate depression, and a score of &#x0003e;47 indicates severe depression [<xref rid="B23-nutrients-10-00329" ref-type="bibr">23</xref>]. The maximum total score is 63, whereas the minimum is 0.</p></sec><sec id="sec2dot2dot5-nutrients-10-00329"><title>2.2.5. State-Trait Anxiety Inventory (STAI)</title><p>Patients&#x02019; anxiety was measured using the 20-items state-trait anxiety inventory (STAI). Each of 20 items related to anxiety was scored as 1 (not at all), 2 (somewhat), 3 (moderately), 4 (very much) with higher score indicating more anxiety.</p><p>The scale is scored by summing the 20 responses (range 20&#x02013;80) [<xref rid="B24-nutrients-10-00329" ref-type="bibr">24</xref>].</p></sec><sec id="sec2dot2dot6-nutrients-10-00329"><title>2.2.6. Clinical and Laboratory Assessment</title><p>Medical history and physical examination had been performed for all patients. Laboratory tests included renal and liver function test, albumin, &#x003b1; fetoprotein, hemogram, prothrombin time index, fasting blood sugar, and venous ammonia concentration. The ammonia was determined according to the enxymatic determination of ammonia with glutamate dehydrogenase in a rapid and interference-free photometric determination (340 nanometer) of NH<sub>4</sub><sup>+</sup> in native blood plasma as according to De Fonseca-Wollheim method [<xref rid="B25-nutrients-10-00329" ref-type="bibr">25</xref>]. Blood was immediately taken by refrigerated transport sent to the laboratory for determination within 15 min from blood sampling. To stage cirrhosis Child-Pugh score was carried out.</p><p>Cirrhosis and Viral etiology were evaluated, considering alcohol consumption for cirrhosis and measuring through ELISA HBsAg levels and anti HCV levels for viral tests. When indicated, medical examination for autoimmune liver disease, Wilson disease, hemochromatosis, and Budd-Chiari Syndrome were performed.</p></sec><sec id="sec2dot2dot7-nutrients-10-00329"><title>2.2.7. Neurological Assessment</title><p>Detailed neurological, psychiatric and mental state assessment had been performed to avoid undiagnosed psychiatric disorders.</p></sec><sec id="sec2dot2dot8-nutrients-10-00329"><title>2.2.8. Efficacy and Tolerability Assessment</title><p>The primary efficacy measures were changed at the beginning and at the end of the study period in aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transpeptidase (&#x003b3;-GT), albumin, alkaline phosphatase (ALP), prothrombin time, and ammonia.</p><p>Laboratory assessments included hemochrome, glycemia, creatininemia, and blood urea were monitored at baseline and monthly until the end of the trial. Each subject of both the groups underwent ultrasonography (US) examination of the liver, electrocardiography, and blood pressure with the use of standard techniques [<xref rid="B26-nutrients-10-00329" ref-type="bibr">26</xref>].</p></sec></sec><sec id="sec2dot3-nutrients-10-00329"><title>2.3. Statistical Analysis</title><p>Descriptive statistics, chi-square tests (for categorical variables), and <italic>t</italic>-tests (for continuous variables) were used to compare demographic and clinical characteristics. <italic>p</italic> values &#x02264; 0.05 were considered to be statistically significant. Means, actual numbers, and percentages were used to describe data. Statistical Analyses were performed by two-way analysis of variance (ANOVA), as well as by controlling for Bonferroni&#x02019;s multiple correction.</p></sec></sec><sec id="sec3-nutrients-10-00329"><title>3. Results</title><p>Demographics characteristics were similar between the two groups at baseline. At enrolment, no significant differences were observed in biohumoral tests, at etiologic factors in cirrhosis (<xref ref-type="table" rid="nutrients-10-00329-t001">Table 1</xref>).</p><sec id="sec3dot1-nutrients-10-00329"><title>3.1. Effects of RV on Biohumoral Findings</title><p>In the group that were treated with RV, we observed a significant decrease (<italic>p</italic> &#x0003c; 0.001) in urea, in NH4, in AST, in ALT, and &#x003b3;-GT.</p><p>In the placebo group we observed a decrease (<italic>p</italic> &#x0003c; 0.05) in AST and ALT.</p><p>The comparison between RV group and placebo group shows a significant decrease in NH4 (<italic>p</italic> &#x0003c; 0.001) in AST (<italic>p</italic> &#x0003c; 0.001) and in ALT (<italic>p</italic> &#x0003c; 0.001) (<xref ref-type="table" rid="nutrients-10-00329-t002">Table 2</xref>).</p></sec><sec id="sec3dot2-nutrients-10-00329"><title>3.2. Effects of RV in Depression, in Anxiety and in Quality of Life</title><p>Anxiety and quality of life. The comparison between before and after RV treatment showed a decreased in BDI <italic>p</italic> &#x0003c; 0.001 in STAI (<italic>p</italic> &#x0003c; 0.001) and increased in physical function (<italic>p</italic> &#x0003c; 0.001), in role physical (<italic>p</italic> &#x0003c; 0.05), in Body pain (<italic>p</italic> &#x0003c; 0.001), in general health (<italic>p</italic> &#x0003c; 0.001), in vitality (<italic>p</italic> = 0.002), and in social function (<italic>p</italic> &#x0003c; 0.001).</p><p>In the comparison between the RV group and the placebo group, we observed a decrease in BDI (<italic>p</italic> &#x0003c; 0.001), in STAI (<italic>p</italic> &#x0003c; 0.001), an improvement in physical function (<italic>p</italic> &#x0003c; 0.001), in role physical (<italic>p</italic> &#x0003c; 0.05), in body pain (<italic>p</italic> &#x0003c; 0.05), in general health (<italic>p</italic> &#x0003c; 0.001), in vitality (<italic>p</italic> &#x0003c; 0.05), and in social function (<italic>p</italic> &#x0003c; 0.001) (<xref ref-type="fig" rid="nutrients-10-00329-f002">Figure 2</xref>; <xref ref-type="table" rid="nutrients-10-00329-t003">Table 3</xref>).</p></sec><sec id="sec3dot3-nutrients-10-00329"><title>3.3. Adverse Events</title><p>No serious adverse events have been observed in both groups.</p></sec></sec><sec id="sec4-nutrients-10-00329"><title>4. Discussion</title><p>In the present study, we tested a cohort of patients with MHE. Our result reveals the presence of moderate depression, anxiety, and a decrease of QoL in subjects with MHE.</p><p>The pathogenesis of MHE has been associated with impairment in cerebral energy metabolism with alteration in glucose utilization, glycolysis, and mitochondrial dysfunction. It is thought that impaired mitochondrial function and the down-regulation of the expression of key anti-oxidation enxzymes contribute to an increase in oxidative damage to membrane lipids [<xref rid="B27-nutrients-10-00329" ref-type="bibr">27</xref>,<xref rid="B28-nutrients-10-00329" ref-type="bibr">28</xref>,<xref rid="B29-nutrients-10-00329" ref-type="bibr">29</xref>,<xref rid="B30-nutrients-10-00329" ref-type="bibr">30</xref>,<xref rid="B31-nutrients-10-00329" ref-type="bibr">31</xref>,<xref rid="B32-nutrients-10-00329" ref-type="bibr">32</xref>,<xref rid="B33-nutrients-10-00329" ref-type="bibr">33</xref>].</p><p>It has been demonstrated that RV has remarkable health benefits. One of the major etiopathogenetic factors that are involved in the development of HE is represented by abnormal accumulation in the blood of ammonia. Nonetheless although ammonia seems to have a central role in HE, there is evidence that neurotransmission abnormalities, injury to astrocytes, and microglia activation contribute to the development of HE [<xref rid="B34-nutrients-10-00329" ref-type="bibr">34</xref>,<xref rid="B35-nutrients-10-00329" ref-type="bibr">35</xref>]. Hyperammonemia represents a major contributing factor for the development of HE. Recent studies have demonstrated that ammonia exerts effect on many signal transduction pathways, gene expression, and post-translational modifications and influences gene expressions via alteration in micro-RNA expression [<xref rid="B36-nutrients-10-00329" ref-type="bibr">36</xref>]. Micro-RNAs are small non-coding RNA sequences that play a role in gene silencing at the level of gene transcription as well as translation, and can be regulated by oxidative stress. In RV group we observed a decreased in ammonia serum levels, in depression, in anxiety, and an increase in quality of life (QoL).</p><p>RV improves astroglial function and it may play a role in the modulation of glutamatergic metabolism having a cytoprotective action [<xref rid="B37-nutrients-10-00329" ref-type="bibr">37</xref>,<xref rid="B38-nutrients-10-00329" ref-type="bibr">38</xref>].</p><p>Neurotransmission impairment, caused by an imbalance between the inhibitory and excitatory neurotransmission systems toward a net increase of inhibitory system, is suggested to participate in the pathogenesis of the disease. Several reported findings are consistent with an increase in &#x003b3;-aminobutiric acid ergic (GABAergic) tone in HE, such as a greater resistance to drug that decreases GABEergic agonists [<xref rid="B39-nutrients-10-00329" ref-type="bibr">39</xref>,<xref rid="B40-nutrients-10-00329" ref-type="bibr">40</xref>]. There is also evidence indicating disturbed glutamatergic tone, such as an increase in cortical release of glutamate (Glu) and a decrease in Glu uptake by astrocytes and neurons, leading to high Glu levels in the brain extracellular fluid, lower expression of the astroglia-specific Glu transporter, and a decrease of Glu receptors. An increase in intra-astrocytic glutamine due to the high ammonia levels seems to be a key factor for the development of Alzheimer type II astrocytes.</p><p>Microglial activation, which progresses with the development of HE and brain edema, and increases in expression of genes coding for proinflammatory cytokines have been documented in HE.</p><p>RV seems to have protective effects in geriatric disorders including Alzheimer&#x02019;s disease. RV can activate SIRT1, which belong to the sirtuine family of proteins [<xref rid="B41-nutrients-10-00329" ref-type="bibr">41</xref>]. SIRT1 is involved in epigenetic processes via histones and nonhistone proteins deacetylation and its-regulated pathway is associated with inflammation, cells viability, senescence, and also metabolism.</p><p>Murine models demonstrated antipsychotic and anxiolytic properties [<xref rid="B42-nutrients-10-00329" ref-type="bibr">42</xref>]. Neurological disorders are thought to occur via oxidative and and inflammatory to the CNS [<xref rid="B43-nutrients-10-00329" ref-type="bibr">43</xref>,<xref rid="B44-nutrients-10-00329" ref-type="bibr">44</xref>,<xref rid="B45-nutrients-10-00329" ref-type="bibr">45</xref>].</p><p>Studies have reported NF-&#x003ba;B, Akt and STAT3 inhibition by RV. Activation of SIRT-1, a protein recently associated with depressive-like states, inhibits NF-&#x003ba;B via histone deacetylation operated by RV [<xref rid="B46-nutrients-10-00329" ref-type="bibr">46</xref>,<xref rid="B47-nutrients-10-00329" ref-type="bibr">47</xref>]. Another SIRT-1 downstream target is represented by AKT, a serine/threonine kinase, which is linked to axonal and neuronal regulation, regeneration and survival [<xref rid="B48-nutrients-10-00329" ref-type="bibr">48</xref>,<xref rid="B49-nutrients-10-00329" ref-type="bibr">49</xref>].</p><p>RV oxidative and glial inflammation modulation had been demonstrated to prevent ammonia toxicity in astroglial cells.</p><p>High levels of ammonia can reduce serotonin and noradrenaline levels in the CNS, resulting in low alertness and attention-associated sleep complaints [<xref rid="B10-nutrients-10-00329" ref-type="bibr">10</xref>]. Neurobehavioral abnormalities are the major clinical component of HE and have shown to be associated with increased levels of inflammatory cytokines [<xref rid="B50-nutrients-10-00329" ref-type="bibr">50</xref>]. RV may serve as an antidepressant agent, also exerting anti-inflammatory effects [<xref rid="B51-nutrients-10-00329" ref-type="bibr">51</xref>,<xref rid="B52-nutrients-10-00329" ref-type="bibr">52</xref>] and alleviating the consequence of stress with alterations involvement in the immune functions in brain that cause deleterious modifications in the neuronal signaling [<xref rid="B53-nutrients-10-00329" ref-type="bibr">53</xref>].</p><p>The decrease in depression justifies the efficacy of RV in depressed patients with RV.</p><p>The pathophysiological mechanisms involved in HE were inflammation, oxidative stress, impaired blood-brain barrier, permeability, neurotoxins, and impaired energy metabolism of the brain [<xref rid="B54-nutrients-10-00329" ref-type="bibr">54</xref>,<xref rid="B55-nutrients-10-00329" ref-type="bibr">55</xref>,<xref rid="B56-nutrients-10-00329" ref-type="bibr">56</xref>,<xref rid="B57-nutrients-10-00329" ref-type="bibr">57</xref>,<xref rid="B58-nutrients-10-00329" ref-type="bibr">58</xref>].</p><p>Another pathogenic mechanism in HE associated with energy disturbances is the alteration in neurotransmission system, such as the glutamatergic and GABA-ergic systems, resulting in neuronal disinhibition. In vivo preclinical studies had also proposed the involvement of CNS neurotransmitters, including catecholamines, glutamate, GABA, histamine, serotonin, and melatonin [<xref rid="B59-nutrients-10-00329" ref-type="bibr">59</xref>,<xref rid="B60-nutrients-10-00329" ref-type="bibr">60</xref>,<xref rid="B61-nutrients-10-00329" ref-type="bibr">61</xref>,<xref rid="B62-nutrients-10-00329" ref-type="bibr">62</xref>,<xref rid="B63-nutrients-10-00329" ref-type="bibr">63</xref>,<xref rid="B64-nutrients-10-00329" ref-type="bibr">64</xref>,<xref rid="B65-nutrients-10-00329" ref-type="bibr">65</xref>].</p><p>In animal experimental models, RV shows a potent inhibitory monoamine oxidase A and oxidase B and activate serotonine and noradrenaline system [<xref rid="B66-nutrients-10-00329" ref-type="bibr">66</xref>,<xref rid="B67-nutrients-10-00329" ref-type="bibr">67</xref>,<xref rid="B68-nutrients-10-00329" ref-type="bibr">68</xref>,<xref rid="B69-nutrients-10-00329" ref-type="bibr">69</xref>,<xref rid="B70-nutrients-10-00329" ref-type="bibr">70</xref>].</p><p>There are limited data showing the consequences of RV intake regarding the effects in humans.</p><p>This study has several limitations. In fact, we excluded patients with poor HRQoL due to their use of forbidden medications, which could also explain the lack of major changes. We also did not examine confounding factors or potential factors of depressed patients with MHE because the numbers of patients were not statistically powerful.</p><p>Such studies need to be increased in number in order to evaluate the role of RV as a modulator of behaviour in MHE patients. However, treatment of minimal HE remains a huge unmet need and a big concerted effort is needed to better defines the multiple pathophysiological mechanisms.</p></sec><sec id="sec5-nutrients-10-00329"><title>5. Conclusions</title><p>This clinical trial suggests that Resveratrol, as carnitine derivates and sylibin [<xref rid="B71-nutrients-10-00329" ref-type="bibr">71</xref>,<xref rid="B72-nutrients-10-00329" ref-type="bibr">72</xref>,<xref rid="B73-nutrients-10-00329" ref-type="bibr">73</xref>] is helpful in reducing ammonia serum levels and exhibit sufficient bioavailability at the dosages used without any adverse events. Thus, this study provide a rationale for further testing of resveratrol ub future clinical trials and for studying its effectiveness in treating other neurological disorders.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was funded by MIUR.</p></ack><notes><title>Author Contributions</title><p>All authors contributed in the same way to the manuscript and read and approved the final version.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest</p></notes><ref-list><title>References</title><ref id="B1-nutrients-10-00329"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>M.</given-names></name><name><surname>Vacante</surname><given-names>M.</given-names></name><name><surname>Bertino</surname><given-names>G.</given-names></name><name><surname>Neri</surname><given-names>S.</given-names></name><name><surname>Malaguarnera</surname><given-names>M.</given-names></name><name><surname>Gargante</surname><given-names>M.P.</given-names></name><name><surname>Motta</surname><given-names>M.</given-names></name><name><surname>Lupo</surname><given-names>L.</given-names></name><name><surname>Chisari</surname><given-names>G.</given-names></name><name><surname>Bruno</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>The supplementation of acetyl-<sc>l</sc>-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-&#x003b1; 2b plus ribavirin</article-title><source>J. Interferon Cytokine Res.</source><year>2011</year><volume>31</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1089/jir.2011.0010</pub-id><pub-id pub-id-type="pmid">21923249</pub-id></element-citation></ref><ref id="B2-nutrients-10-00329"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>J.H.</given-names></name><name><surname>Stine</surname><given-names>J.G.</given-names></name></person-group><article-title>Review article: Prescribing medications in patients with cirrhosis&#x02014;A practical guide</article-title><source>Aliment. Pharmacol. Ther.</source><year>2013</year><volume>37</volume><fpage>1132</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1111/apt.12324</pub-id><pub-id pub-id-type="pmid">23638982</pub-id></element-citation></ref><ref id="B3-nutrients-10-00329"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farris</surname><given-names>P.</given-names></name><name><surname>Krutmann</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.-H.</given-names></name><name><surname>McDaniel</surname><given-names>D.</given-names></name><name><surname>Krol</surname><given-names>Y.</given-names></name></person-group><article-title>Resveratrol: A unique antioxidant offering a multi-mechanistic approach for treating aging skin</article-title><source>J. Drugs Dermatol.</source><year>2013</year><volume>12</volume><fpage>1389</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">24301240</pub-id></element-citation></ref><ref id="B4-nutrients-10-00329"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00160;vajger</surname><given-names>U.</given-names></name><name><surname>Jeras</surname><given-names>M.</given-names></name></person-group><article-title>Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases</article-title><source>Int. Rev. Immunol.</source><year>2012</year><volume>31</volume><fpage>202</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.3109/08830185.2012.665108</pub-id><pub-id pub-id-type="pmid">22587021</pub-id></element-citation></ref><ref id="B5-nutrients-10-00329"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campagna</surname><given-names>M.</given-names></name><name><surname>Rivas</surname><given-names>C.</given-names></name></person-group><article-title>Antiviral activity of resveratrol</article-title><source>Biochem. Soc. Trans.</source><year>2010</year><volume>38</volume><fpage>50</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1042/BST0380050</pub-id><pub-id pub-id-type="pmid">20074034</pub-id></element-citation></ref><ref id="B6-nutrients-10-00329"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clouser</surname><given-names>C.L.</given-names></name><name><surname>Chauhan</surname><given-names>J.</given-names></name><name><surname>Bess</surname><given-names>M.A.</given-names></name><name><surname>van Oploo</surname><given-names>J.L.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Dimick-Gray</surname><given-names>S.</given-names></name><name><surname>Mansky</surname><given-names>L.M.</given-names></name><name><surname>Patterson</surname><given-names>S.E.</given-names></name></person-group><article-title>Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2012</year><volume>22</volume><fpage>6642</fpage><lpage>6646</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.08.108</pub-id><pub-id pub-id-type="pmid">23010273</pub-id></element-citation></ref><ref id="B7-nutrients-10-00329"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X.-H.</given-names></name><name><surname>Zang</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X.Q.</given-names></name><name><surname>Liu</surname><given-names>E.M.</given-names></name></person-group><article-title>Resveratrol Inhibits respiratory syncytial virus-induced IL-6 production, decreases viral replication, and downregulates TRIF expression in airway epithelial cells</article-title><source>Inflammation</source><year>2012</year><volume>35</volume><fpage>1392</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1007/s10753-012-9452-7</pub-id><pub-id pub-id-type="pmid">22391746</pub-id></element-citation></ref><ref id="B8-nutrients-10-00329"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>G.</given-names></name><name><surname>Pai</surname><given-names>R.S.</given-names></name></person-group><article-title>Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS</article-title><source>J. Control Release</source><year>2014</year><volume>194</volume><fpage>178</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.09.002</pub-id><pub-id pub-id-type="pmid">25217813</pub-id></element-citation></ref><ref id="B9-nutrients-10-00329"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluyen</surname><given-names>J.K.</given-names></name><name><surname>Ton</surname><given-names>Q.N.</given-names></name><name><surname>Tran</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>A.E.</given-names></name><name><surname>Gottlieb</surname><given-names>H.B.</given-names></name><name><surname>Bellanger</surname><given-names>R.A.</given-names></name></person-group><article-title>Resveratrol: Potential as anticancer agent</article-title><source>J. Diet. Suppl.</source><year>2012</year><volume>9</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.3109/19390211.2011.650842</pub-id><pub-id pub-id-type="pmid">22432802</pub-id></element-citation></ref><ref id="B10-nutrients-10-00329"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>From French Paradox to cancer treatment: Anti-cancer activities and mechanisms of resveratrol</article-title><source>Anti-Cancer Agents Med. Chem.</source><year>2014</year><volume>14</volume><fpage>806</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.2174/1871520614666140521121722</pub-id></element-citation></ref><ref id="B11-nutrients-10-00329"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennisi</surname><given-names>M.</given-names></name><name><surname>Bertino</surname><given-names>G.</given-names></name><name><surname>Gagliano</surname><given-names>C.</given-names></name><name><surname>Malaguarnera</surname><given-names>M.</given-names></name><name><surname>Bella</surname><given-names>R.</given-names></name><name><surname>Borz&#x000ec;</surname><given-names>A.M.</given-names></name><name><surname>Madeddu</surname><given-names>R.</given-names></name><name><surname>Malaguarnera</surname><given-names>G.</given-names></name></person-group><article-title>Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-&#x003b1;-2b and Ribavirin Reduces Sleep Disturbance</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><elocation-id>897</elocation-id><pub-id pub-id-type="doi">10.3390/nu9080897</pub-id><pub-id pub-id-type="pmid">28820468</pub-id></element-citation></ref><ref id="B12-nutrients-10-00329"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magaji</surname><given-names>M.G.</given-names></name><name><surname>Iniaghe</surname><given-names>L.O.</given-names></name><name><surname>Abolarin</surname><given-names>M.</given-names></name><name><surname>Abdullahi</surname><given-names>O.I.</given-names></name><name><surname>Magaji</surname><given-names>R.A.</given-names></name></person-group><article-title>Neurobehavioural evaluation of resveratrol in murine models of anxiety and schizophrenia</article-title><source>Metab. Brain Dis.</source><year>2017</year><volume>32</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1007/s11011-016-9927-6</pub-id><pub-id pub-id-type="pmid">27878417</pub-id></element-citation></ref><ref id="B13-nutrients-10-00329"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howitz</surname><given-names>K.T.</given-names></name><name><surname>Bitterman</surname><given-names>K.J.</given-names></name><name><surname>Cohen</surname><given-names>H.Y.</given-names></name><name><surname>Lamming</surname><given-names>D.W.</given-names></name><name><surname>Lavu</surname><given-names>S.</given-names></name><name><surname>Wood</surname><given-names>J.G.</given-names></name><name><surname>Zipkin</surname><given-names>R.E.</given-names></name><name><surname>Chung</surname><given-names>P.</given-names></name><name><surname>Kisielewski</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan</article-title><source>Nature</source><year>2003</year><volume>425</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nature01960</pub-id><pub-id pub-id-type="pmid">12939617</pub-id></element-citation></ref><ref id="B14-nutrients-10-00329"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>V.</given-names></name><name><surname>Nestler</surname><given-names>E.J.</given-names></name></person-group><article-title>The molecular neurobiology of depression</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>894</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1038/nature07455</pub-id><pub-id pub-id-type="pmid">18923511</pub-id></element-citation></ref><ref id="B15-nutrients-10-00329"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conn</surname><given-names>H.O.</given-names></name></person-group><article-title>A clinical hepatologist&#x02019;s predictions about non-absorbed carbohydrates for the early twenty-first century</article-title><source>Scand. J. Gastroenterol.</source><year>1997</year><volume>222</volume><fpage>88</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1080/00365521.1997.11720727</pub-id><pub-id pub-id-type="pmid">9145456</pub-id></element-citation></ref><ref id="B16-nutrients-10-00329"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Child</surname><given-names>C.G.</given-names></name><name><surname>Turcotte</surname><given-names>J.G.</given-names></name></person-group><article-title>Surgery and portal hypertension</article-title><source>The Liver and Portal Hypertension</source><person-group person-group-type="editor"><name><surname>Child</surname><given-names>C.G.</given-names></name></person-group><publisher-name>Saunders</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>1964</year><fpage>50</fpage><lpage>64</lpage></element-citation></ref><ref id="B17-nutrients-10-00329"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferenci</surname><given-names>P.</given-names></name><name><surname>Lockwood</surname><given-names>A.</given-names></name><name><surname>Mullen</surname><given-names>K.</given-names></name><name><surname>Tarter</surname><given-names>R.</given-names></name><name><surname>Weissenborn</surname><given-names>K.</given-names></name><name><surname>Blei</surname><given-names>A.T.</given-names></name></person-group><article-title>Hepatic encephalopathy&#x02014;Definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998</article-title><source>Hepatology</source><year>2002</year><volume>35</volume><fpage>716</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1053/jhep.2002.31250</pub-id><pub-id pub-id-type="pmid">11870389</pub-id></element-citation></ref><ref id="B18-nutrients-10-00329"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissenborn</surname><given-names>K.</given-names></name><name><surname>Ennen</surname><given-names>J.C.</given-names></name><name><surname>Schomerus</surname><given-names>H.</given-names></name><name><surname>R&#x000fc;ckert</surname><given-names>N.</given-names></name><name><surname>Hecker</surname><given-names>H.</given-names></name></person-group><article-title>Neuropsychological characterization of hepatic encephalopathy</article-title><source>J. Hepatol.</source><year>2001</year><volume>34</volume><fpage>768</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(01)00026-5</pub-id><pub-id pub-id-type="pmid">11434627</pub-id></element-citation></ref><ref id="B19-nutrients-10-00329"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>J.</given-names></name><name><surname>Kosinski</surname><given-names>M.</given-names></name><name><surname>Snow</surname><given-names>K.K.</given-names></name><name><surname>Gandek</surname><given-names>B.</given-names></name></person-group><source>SF-36 Health Survey: Manual and Interpretation Guide</source><publisher-name>The Health Institute, New England Medical Center</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>1993</year></element-citation></ref><ref id="B20-nutrients-10-00329"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonkovsky</surname><given-names>H.L.</given-names></name><name><surname>Woolley</surname><given-names>J.M.</given-names></name></person-group><article-title>Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group</article-title><source>Hepatology</source><year>1999</year><volume>29</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1002/hep.510290124</pub-id><pub-id pub-id-type="pmid">9862876</pub-id></element-citation></ref><ref id="B21-nutrients-10-00329"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>G.R.</given-names></name></person-group><article-title>Hepatitis C virus infection: Quality of life and side effects of treatment</article-title><source>J. Hepatol.</source><year>1999</year><volume>31</volume><fpage>250</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(99)80411-5</pub-id><pub-id pub-id-type="pmid">10622597</pub-id></element-citation></ref><ref id="B22-nutrients-10-00329"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosso</surname><given-names>G.</given-names></name><name><surname>Micek</surname><given-names>A.</given-names></name><name><surname>Godos</surname><given-names>J.</given-names></name><name><surname>Pajak</surname><given-names>A.</given-names></name><name><surname>Sciacca</surname><given-names>S.</given-names></name><name><surname>Galvano</surname><given-names>F.</given-names></name><name><surname>Giovannucci</surname><given-names>E.L.</given-names></name></person-group><article-title>Dietary Flavonoid and Lignan Intake and Mortality in Prospective Cohort Studies: Systematic Review and Dose-Response Meta-Analysis</article-title><source>Am. J. Epidemiol.</source><year>2017</year><volume>185</volume><fpage>1304</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1093/aje/kww207</pub-id><pub-id pub-id-type="pmid">28472215</pub-id></element-citation></ref><ref id="B23-nutrients-10-00329"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>A.</given-names></name><name><surname>Steer</surname><given-names>R.</given-names></name><name><surname>Garbin</surname><given-names>M.</given-names></name></person-group><article-title>Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation</article-title><source>Clin. Psychol. Rev.</source><year>1988</year><volume>8</volume><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/0272-7358(88)90050-5</pub-id></element-citation></ref><ref id="B24-nutrients-10-00329"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spielberger</surname><given-names>C.D.</given-names></name></person-group><source>Manual for the State&#x02014;Trait Anxiety Inventory: STAI (Form Y)</source><publisher-name>Consulting Psychologists Press</publisher-name><publisher-loc>Palo Alto, CA, USA</publisher-loc><year>1983</year></element-citation></ref><ref id="B25-nutrients-10-00329"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Da Fonseca-Wollheim</surname><given-names>F.</given-names></name></person-group><article-title>Direct determination of plasma ammonia without deproteinization. An improved enzymic determination of ammonia, II (author&#x02019;s transl)</article-title><source>Z. Klin. Chem. Klin. Biochem.</source><year>1973</year><volume>11</volume><fpage>426</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">4155181</pub-id></element-citation></ref><ref id="B26-nutrients-10-00329"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latteri</surname><given-names>S.</given-names></name><name><surname>Malaguarnera</surname><given-names>G.</given-names></name><name><surname>Mannino</surname><given-names>M.</given-names></name><name><surname>Pesce</surname><given-names>A.</given-names></name><name><surname>Curr&#x000f2;</surname><given-names>G.</given-names></name><name><surname>Tamburrini</surname><given-names>S.</given-names></name><name><surname>Scuderi</surname><given-names>M.</given-names></name></person-group><article-title>Ultrasound as point of care in management of polytrauma and its complication</article-title><source>J. Ultrasound</source><year>2017</year><volume>20</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1007/s40477-017-0252-7</pub-id><pub-id pub-id-type="pmid">28593009</pub-id></element-citation></ref><ref id="B27-nutrients-10-00329"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flamm</surname><given-names>S.L.</given-names></name></person-group><article-title>Covert Hepatic Encephalopathy: Who Should Be Tested and Treated?</article-title><source>Clin. Liver Dis.</source><year>2015</year><volume>19</volume><fpage>473</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2015.04.007</pub-id><pub-id pub-id-type="pmid">26195202</pub-id></element-citation></ref><ref id="B28-nutrients-10-00329"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>G.</given-names></name><name><surname>Latteri</surname><given-names>S.</given-names></name><name><surname>Catania</surname><given-names>V.E.</given-names></name><name><surname>Malaguarnera</surname><given-names>M.</given-names></name></person-group><article-title>Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels</article-title><source>J. Thorac. Dis.</source><year>2017</year><volume>9</volume><fpage>2332</fpage><lpage>2336</lpage><pub-id pub-id-type="doi">10.21037/jtd.2017.08.67</pub-id><pub-id pub-id-type="pmid">28932535</pub-id></element-citation></ref><ref id="B29-nutrients-10-00329"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>G.</given-names></name><name><surname>Catania</surname><given-names>V.E.</given-names></name><name><surname>Francaviglia</surname><given-names>A.</given-names></name><name><surname>Malaguarnera</surname><given-names>M.</given-names></name><name><surname>Drago</surname><given-names>F.</given-names></name><name><surname>Motta</surname><given-names>M.</given-names></name><name><surname>Latteri</surname><given-names>S.</given-names></name></person-group><article-title>Lipoprotein (a) in patients with hepatocellular carcinoma and portal vein thrombosis</article-title><source>Aging Clin. Exp. Res.</source><year>2017</year><volume>29</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1007/s40520-016-0653-z</pub-id><pub-id pub-id-type="pmid">27822883</pub-id></element-citation></ref><ref id="B30-nutrients-10-00329"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Verde</surname><given-names>M.</given-names></name><name><surname>Mule</surname><given-names>S.</given-names></name><name><surname>Zappala</surname><given-names>G.</given-names></name><name><surname>Privitera</surname><given-names>G.</given-names></name><name><surname>Maugeri</surname><given-names>G.</given-names></name><name><surname>Pecora</surname><given-names>F.</given-names></name><name><surname>Marranzano</surname><given-names>M.</given-names></name></person-group><article-title>Higher adherence to the Mediterranean diet is inversely associated with having hypertension: Is low salt intake a mediating factor?</article-title><source>Int. J. Food Sci. Nutr.</source><year>2018</year><volume>69</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1080/09637486.2017.1350941</pub-id><pub-id pub-id-type="pmid">28705075</pub-id></element-citation></ref><ref id="B31-nutrients-10-00329"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platania</surname><given-names>A.</given-names></name><name><surname>Zappala</surname><given-names>G.</given-names></name><name><surname>Mirabella</surname><given-names>M.U.</given-names></name><name><surname>Gullo</surname><given-names>C.</given-names></name><name><surname>Mellini</surname><given-names>G.</given-names></name><name><surname>Beneventano</surname><given-names>G.</given-names></name><name><surname>Maugeri</surname><given-names>G.</given-names></name><name><surname>Marranzano</surname><given-names>M.</given-names></name></person-group><article-title>Association between Mediterranean diet adherence and dyslipidaemia in a cohort of adults living in the Mediterranean area</article-title><source>Int. J. Food Sci. Nutr.</source><year>2017</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1080/09637486.2017.1389860</pub-id><pub-id pub-id-type="pmid">29063802</pub-id></element-citation></ref><ref id="B32-nutrients-10-00329"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zappala</surname><given-names>G.</given-names></name><name><surname>Buscemi</surname><given-names>S.</given-names></name><name><surname>Mule</surname><given-names>S.</given-names></name><name><surname>La Verde</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Urso</surname><given-names>M.</given-names></name><name><surname>Corleo</surname><given-names>D.</given-names></name><name><surname>Marranzano</surname><given-names>M.</given-names></name></person-group><article-title>High adherence to Mediterranean diet, but not individual foods or nutrients, is associated with lower likelihood of being obese in a Mediterranean cohort</article-title><source>Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2017</year><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="B33-nutrients-10-00329"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobermin</surname><given-names>L.D.</given-names></name><name><surname>Wartchow</surname><given-names>K.M.</given-names></name><name><surname>Flores</surname><given-names>M.P.</given-names></name><name><surname>Leite</surname><given-names>M.C.</given-names></name><name><surname>Quincozes-Santos</surname><given-names>A.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>C.A.</given-names></name></person-group><article-title>Ammonia-induced oxidative damage in neurons is prevented by resveratrol and lipoic acid with participation of heme oxygenase 1</article-title><source>Neurotoxicology</source><year>2015</year><volume>49</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.neuro.2015.05.005</pub-id><pub-id pub-id-type="pmid">26003724</pub-id></element-citation></ref><ref id="B34-nutrients-10-00329"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montana</surname><given-names>V.</given-names></name><name><surname>Verkhratsky</surname><given-names>A.</given-names></name><name><surname>Parpura</surname><given-names>V.</given-names></name></person-group><article-title>Pathological role for exocytotic glutamate release from astrocytes in hepatic encephalopathy</article-title><source>Curr. Neuropharmacol.</source><year>2014</year><volume>12</volume><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.2174/1570159X12666140903094700</pub-id><pub-id pub-id-type="pmid">25342940</pub-id></element-citation></ref><ref id="B35-nutrients-10-00329"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;rg</surname><given-names>B.</given-names></name><name><surname>Qvartskhava</surname><given-names>N.</given-names></name><name><surname>Bidmon</surname><given-names>H.-J.</given-names></name><name><surname>Palomero-Gallagher</surname><given-names>N.</given-names></name><name><surname>Kircheis</surname><given-names>G.</given-names></name><name><surname>Zilles</surname><given-names>K.</given-names></name><name><surname>H&#x000e4;ussinger</surname><given-names>D.</given-names></name></person-group><article-title>Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><fpage>256</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/hep.23656</pub-id><pub-id pub-id-type="pmid">20583283</pub-id></element-citation></ref><ref id="B36-nutrients-10-00329"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karababa</surname><given-names>A.</given-names></name><name><surname>G&#x000f6;rg</surname><given-names>B.</given-names></name><name><surname>Schliess</surname><given-names>F.</given-names></name><name><surname>H&#x000e4;ussinger</surname><given-names>D.</given-names></name></person-group><article-title><italic>O</italic>-GlcNAcylation as a novel ammonia-induced posttranslational protein modification in cultured rat astrocytes</article-title><source>Metab. Brain Dis.</source><year>2014</year><volume>29</volume><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1007/s11011-013-9454-7</pub-id><pub-id pub-id-type="pmid">24292976</pub-id></element-citation></ref><ref id="B37-nutrients-10-00329"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Almeida</surname><given-names>L.M.V.</given-names></name><name><surname>Pi&#x000f1;eiro</surname><given-names>C.C.</given-names></name><name><surname>Leite</surname><given-names>M.C.</given-names></name><name><surname>Brolese</surname><given-names>G.</given-names></name><name><surname>Tramontina</surname><given-names>F.</given-names></name><name><surname>Feoli</surname><given-names>A.M.</given-names></name><name><surname>Gottfried</surname><given-names>C.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>C.A.</given-names></name></person-group><article-title>Resveratrol increases glutamate uptake, glutathione content, and S100B secretion in cortical astrocyte cultures</article-title><source>Cell. Mol. Neurobiol.</source><year>2007</year><volume>27</volume><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1007/s10571-007-9152-2</pub-id><pub-id pub-id-type="pmid">17554623</pub-id></element-citation></ref><ref id="B38-nutrients-10-00329"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quincozes-Santos</surname><given-names>A.</given-names></name><name><surname>Gottfried</surname><given-names>C.</given-names></name></person-group><article-title>Resveratrol modulates astroglial functions: Neuroprotective hypothesis</article-title><source>Ann. N Y. Acad. Sci.</source><year>2011</year><volume>1215</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05857.x</pub-id><pub-id pub-id-type="pmid">21261643</pub-id></element-citation></ref><ref id="B39-nutrients-10-00329"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felipo</surname><given-names>V.</given-names></name></person-group><article-title>Hepatic encephalopathy: Effects of liver failure on brain function</article-title><source>Nat. Rev. Neurosci.</source><year>2013</year><volume>14</volume><fpage>851</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/nrn3587</pub-id><pub-id pub-id-type="pmid">24149188</pub-id></element-citation></ref><ref id="B40-nutrients-10-00329"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>G.</given-names></name><name><surname>Vacante</surname><given-names>M.</given-names></name><name><surname>Drago</surname><given-names>F.</given-names></name><name><surname>Bertino</surname><given-names>G.</given-names></name><name><surname>Motta</surname><given-names>M.</given-names></name><name><surname>Giordano</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Endozepine-4 levels are increased in hepatic coma</article-title><source>World J. Gastroenterol.</source><year>2015</year><volume>21</volume><fpage>9103</fpage><lpage>9110</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i30.9103</pub-id><pub-id pub-id-type="pmid">26290636</pub-id></element-citation></ref><ref id="B41-nutrients-10-00329"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulose</surname><given-names>S.M.</given-names></name><name><surname>Thangthaeng</surname><given-names>N.</given-names></name><name><surname>Miller</surname><given-names>M.G.</given-names></name><name><surname>Shukitt-Hale</surname><given-names>B.</given-names></name></person-group><article-title>Effects of pterostilbene and resveratrol on brain and behavior</article-title><source>Neurochem. Int.</source><year>2015</year><volume>89</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2015.07.017</pub-id><pub-id pub-id-type="pmid">26212523</pub-id></element-citation></ref><ref id="B42-nutrients-10-00329"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Y&#x000e1;&#x000f1;ez</surname><given-names>M.</given-names></name><name><surname>Fraiz</surname><given-names>N.</given-names></name><name><surname>Cano</surname><given-names>E.</given-names></name><name><surname>Orallo</surname><given-names>F.</given-names></name></person-group><article-title>Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2006</year><volume>344</volume><fpage>688</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.03.190</pub-id><pub-id pub-id-type="pmid">16631124</pub-id></element-citation></ref><ref id="B43-nutrients-10-00329"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Rosa</surname><given-names>M.</given-names></name><name><surname>Malaguarnera</surname><given-names>G.</given-names></name><name><surname>De Gregorio</surname><given-names>C.</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>F.</given-names></name><name><surname>Mazzarino</surname><given-names>M.C.</given-names></name><name><surname>Malaguarnera</surname><given-names>L.</given-names></name></person-group><article-title>Modulation of chitotriosidase during macrophage differentiation</article-title><source>Cell Biochem. Biophys.</source><year>2013</year><volume>66</volume><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1007/s12013-012-9471-x</pub-id><pub-id pub-id-type="pmid">23152091</pub-id></element-citation></ref><ref id="B44-nutrients-10-00329"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>M.</given-names></name><name><surname>Vacante</surname><given-names>M.</given-names></name><name><surname>Giordano</surname><given-names>M.</given-names></name><name><surname>Motta</surname><given-names>M.</given-names></name><name><surname>Bertino</surname><given-names>G.</given-names></name><name><surname>Pennisi</surname><given-names>M.</given-names></name><name><surname>Neri</surname><given-names>S.</given-names></name><name><surname>Malaguarnera</surname><given-names>M.</given-names></name><name><surname>Li Volti</surname><given-names>G.</given-names></name><name><surname>Galvano</surname><given-names>F.</given-names></name></person-group><article-title><sc>l</sc>-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-&#x003b1; 2b plus ribavirin</article-title><source>World J. Gastroenterol.</source><year>2011</year><volume>17</volume><fpage>4414</fpage><lpage>4420</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i39.4414</pub-id><pub-id pub-id-type="pmid">22110268</pub-id></element-citation></ref><ref id="B45-nutrients-10-00329"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Greca</surname><given-names>G.</given-names></name><name><surname>Santangelo</surname><given-names>A.</given-names></name><name><surname>Primo</surname><given-names>S.</given-names></name><name><surname>Sofia</surname><given-names>M.</given-names></name><name><surname>Latteri</surname><given-names>S.</given-names></name><name><surname>Russello</surname><given-names>D.</given-names></name><name><surname>Magro</surname><given-names>G.</given-names></name></person-group><article-title>Clinical and diagnostic problems of desmoid-type fibromatosis of the mesentery: Case report and review of the literature</article-title><source>Ann. Ital. Chir.</source><year>2014</year><volume>85</volume><!--<pub-id pub-id-type="pii">S2239253X14023226</pub-id>--></element-citation></ref><ref id="B46-nutrients-10-00329"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagul</surname><given-names>P.K.</given-names></name><name><surname>Deepthi</surname><given-names>N.</given-names></name><name><surname>Sultana</surname><given-names>R.</given-names></name><name><surname>Banerjee</surname><given-names>S.K.</given-names></name></person-group><article-title>Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NF&#x003ba;B-p65 and histone 3</article-title><source>J. Nutr. Biochem.</source><year>2015</year><volume>26</volume><fpage>1298</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2015.06.006</pub-id><pub-id pub-id-type="pmid">26298192</pub-id></element-citation></ref><ref id="B47-nutrients-10-00329"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patki</surname><given-names>G.</given-names></name><name><surname>Solanki</surname><given-names>N.</given-names></name><name><surname>Atrooz</surname><given-names>F.</given-names></name><name><surname>Allam</surname><given-names>F.</given-names></name><name><surname>Salim</surname><given-names>S.</given-names></name></person-group><article-title>Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress</article-title><source>Brain Res.</source><year>2013</year><volume>1539</volume><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2013.09.033</pub-id><pub-id pub-id-type="pmid">24096214</pub-id></element-citation></ref><ref id="B48-nutrients-10-00329"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freyberg</surname><given-names>Z.</given-names></name><name><surname>Ferrando</surname><given-names>S.J.</given-names></name><name><surname>Javitch</surname><given-names>J.A.</given-names></name></person-group><article-title>Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action</article-title><source>Am. J. Psychiatry</source><year>2010</year><volume>167</volume><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2009.08121873</pub-id><pub-id pub-id-type="pmid">19917593</pub-id></element-citation></ref><ref id="B49-nutrients-10-00329"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Yue</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by &#x003b2;-amyloid through activation of SIRT1/Akt1 pathway</article-title><source>Biofactors</source><year>2014</year><volume>40</volume><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1002/biof.1149</pub-id><pub-id pub-id-type="pmid">24132831</pub-id></element-citation></ref><ref id="B50-nutrients-10-00329"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldridge</surname><given-names>D.R.</given-names></name><name><surname>Tranah</surname><given-names>E.J.</given-names></name><name><surname>Shawcross</surname><given-names>D.L.</given-names></name></person-group><article-title>Pathogenesis of hepatic encephalopathy: Role of ammonia and systemic inflammation</article-title><source>J. Clin. Exp. Hepatol.</source><year>2015</year><volume>5</volume><fpage>S7</fpage><lpage>S20</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2014.06.004</pub-id><pub-id pub-id-type="pmid">26041962</pub-id></element-citation></ref><ref id="B51-nutrients-10-00329"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnell</surname><given-names>J.E.</given-names></name><name><surname>Lombard</surname><given-names>C.M.</given-names></name><name><surname>Melson</surname><given-names>M.N.</given-names></name><name><surname>Singh</surname><given-names>N.P.</given-names></name><name><surname>Nagarkatti</surname><given-names>M.</given-names></name><name><surname>Nagarkatti</surname><given-names>P.</given-names></name><name><surname>Fadel</surname><given-names>J.R.</given-names></name><name><surname>Wood</surname><given-names>C.S.</given-names></name><name><surname>Wood</surname><given-names>S.K.</given-names></name></person-group><article-title>The protective effects of resveratrol on social stress-induced cytokine release and depressive-like behavior</article-title><source>Brain Behav. Immun.</source><year>2017</year><volume>59</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2016.08.019</pub-id><pub-id pub-id-type="pmid">27592314</pub-id></element-citation></ref><ref id="B52-nutrients-10-00329"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbagallo</surname><given-names>F.</given-names></name><name><surname>Latteri</surname><given-names>S.</given-names></name><name><surname>Sofia</surname><given-names>M.</given-names></name><name><surname>Ricotta</surname><given-names>A.</given-names></name><name><surname>Castello</surname><given-names>G.</given-names></name><name><surname>Chisari</surname><given-names>A.</given-names></name><name><surname>Randazzo</surname><given-names>V.</given-names></name><name><surname>La Greca</surname><given-names>G.</given-names></name></person-group><article-title>Appendicular tuberculosis: The resurgence of an old disease with difficult diagnosis</article-title><source>World J. Gastroenterol.</source><year>2010</year><volume>16</volume><fpage>518</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i4.518</pub-id><pub-id pub-id-type="pmid">20101782</pub-id></element-citation></ref><ref id="B53-nutrients-10-00329"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davinelli</surname><given-names>S.</given-names></name><name><surname>Scapagnini</surname><given-names>G.</given-names></name><name><surname>Marzatico</surname><given-names>F.</given-names></name><name><surname>Nobile</surname><given-names>V.</given-names></name><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Corbi</surname><given-names>G.</given-names></name></person-group><article-title>Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study</article-title><source>Maturitas</source><year>2017</year><volume>96</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2016.11.016</pub-id><pub-id pub-id-type="pmid">28041599</pub-id></element-citation></ref><ref id="B54-nutrients-10-00329"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>S.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Caito</surname><given-names>S.</given-names></name><name><surname>Hwang</surname><given-names>J.-W.</given-names></name><name><surname>Arunachalam</surname><given-names>G.</given-names></name><name><surname>Rahman</surname><given-names>I.</given-names></name></person-group><article-title>Regulation of SIRT1 in cellular functions: Role of polyphenols</article-title><source>Arch. Biochem. Biophys.</source><year>2010</year><volume>501</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2010.05.003</pub-id><pub-id pub-id-type="pmid">20450879</pub-id></element-citation></ref><ref id="B55-nutrients-10-00329"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasinetti</surname><given-names>G.M.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ho</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Dubner</surname><given-names>L.</given-names></name></person-group><article-title>Roles of resveratrol and other grape-derived polyphenols in Alzheimer&#x02019;s disease prevention and treatment</article-title><source>Biochim. Biophys. Acta</source><year>2015</year><volume>1852</volume><fpage>1202</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2014.10.006</pub-id><pub-id pub-id-type="pmid">25315300</pub-id></element-citation></ref><ref id="B56-nutrients-10-00329"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalan</surname><given-names>R.</given-names></name><name><surname>Olde Damink</surname><given-names>S.W.M.</given-names></name><name><surname>Hayes</surname><given-names>P.C.</given-names></name><name><surname>Deutz</surname><given-names>N.E.P.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name></person-group><article-title>Pathogenesis of intracranial hypertension in acute liver failure: Inflammation, ammonia and cerebral blood flow</article-title><source>J. Hepatol.</source><year>2004</year><volume>41</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2004.06.011</pub-id><pub-id pub-id-type="pmid">15464242</pub-id></element-citation></ref><ref id="B57-nutrients-10-00329"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosoi</surname><given-names>C.R.</given-names></name><name><surname>Rose</surname><given-names>C.F.</given-names></name></person-group><article-title>Oxidative stress: A systemic factor implicated in the pathogenesis of hepatic encephalopathy</article-title><source>Metab. Brain Dis.</source><year>2013</year><volume>28</volume><fpage>175</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s11011-012-9351-5</pub-id><pub-id pub-id-type="pmid">23124921</pub-id></element-citation></ref><ref id="B58-nutrients-10-00329"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rama Rao</surname><given-names>K.V.</given-names></name><name><surname>Norenberg</surname><given-names>M.D.</given-names></name></person-group><article-title>Brain energy metabolism and mitochondrial dysfunction in acute and chronic hepatic encephalopathy</article-title><source>Neurochem. Int.</source><year>2012</year><volume>60</volume><fpage>697</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2011.09.007</pub-id><pub-id pub-id-type="pmid">21989389</pub-id></element-citation></ref><ref id="B59-nutrients-10-00329"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zwingmann</surname><given-names>C.</given-names></name></person-group><article-title>The anaplerotic flux and ammonia detoxification in hepatic encephalopathy</article-title><source>Metab. Brain Dis.</source><year>2007</year><volume>22</volume><fpage>235</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1007/s11011-007-9069-y</pub-id><pub-id pub-id-type="pmid">17823857</pub-id></element-citation></ref><ref id="B60-nutrients-10-00329"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yurdaydin</surname><given-names>C.</given-names></name><name><surname>H&#x000f6;rtnagl</surname><given-names>H.</given-names></name><name><surname>Steindl</surname><given-names>P.</given-names></name><name><surname>Zimmermann</surname><given-names>C.</given-names></name><name><surname>Pifl</surname><given-names>C.</given-names></name><name><surname>Singer</surname><given-names>E.A.</given-names></name><name><surname>Roth</surname><given-names>E.</given-names></name><name><surname>Ferenci</surname><given-names>P.</given-names></name></person-group><article-title>Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure</article-title><source>Hepatology</source><year>1990</year><volume>12</volume><fpage>695</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1002/hep.1840120413</pub-id><pub-id pub-id-type="pmid">1698704</pub-id></element-citation></ref><ref id="B61-nutrients-10-00329"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozeva</surname><given-names>V.</given-names></name><name><surname>Tuomisto</surname><given-names>L.</given-names></name><name><surname>Sola</surname><given-names>D.</given-names></name><name><surname>Plumed</surname><given-names>C.</given-names></name><name><surname>Hippel&#x000e4;inen</surname><given-names>M.</given-names></name><name><surname>Butterworth</surname><given-names>R.</given-names></name></person-group><article-title>Increased density of brain histamine H(1) receptors in rats with portacaval anastomosis and in cirrhotic patients with chronic hepatic encephalopathy</article-title><source>Hepatology</source><year>2001</year><volume>33</volume><fpage>1370</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1053/jhep.2001.25090</pub-id><pub-id pub-id-type="pmid">11391525</pub-id></element-citation></ref><ref id="B62-nutrients-10-00329"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steindl</surname><given-names>P.E.</given-names></name><name><surname>Finn</surname><given-names>B.</given-names></name><name><surname>Bendok</surname><given-names>B.</given-names></name><name><surname>Rothke</surname><given-names>S.</given-names></name><name><surname>Zee</surname><given-names>P.C.</given-names></name><name><surname>Blei</surname><given-names>A.T.</given-names></name></person-group><article-title>Disruption of the diurnal rhythm of plasma melatonin in cirrhosis</article-title><source>Ann. Intern. Med.</source><year>1995</year><volume>123</volume><fpage>274</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-123-4-199508150-00005</pub-id><pub-id pub-id-type="pmid">7611593</pub-id></element-citation></ref><ref id="B63-nutrients-10-00329"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>D.F.</given-names></name><name><surname>Jones</surname><given-names>E.A.</given-names></name></person-group><article-title>Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system</article-title><source>Lancet</source><year>1982</year><volume>319</volume><fpage>18</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(82)92559-4</pub-id></element-citation></ref><ref id="B64-nutrients-10-00329"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahboucha</surname><given-names>S.</given-names></name><name><surname>Pomier-Layrargues</surname><given-names>G.</given-names></name><name><surname>Butterworth</surname><given-names>R.F.</given-names></name></person-group><article-title>Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy</article-title><source>Metab. Brain Dis.</source><year>2004</year><volume>19</volume><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1023/B:MEBR.0000043974.89820.22</pub-id><pub-id pub-id-type="pmid">15554420</pub-id></element-citation></ref><ref id="B65-nutrients-10-00329"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Als-Nielsen</surname><given-names>B.</given-names></name><name><surname>Gluud</surname><given-names>L.L.</given-names></name><name><surname>Gluud</surname><given-names>C.</given-names></name></person-group><article-title>Dopaminergic agonists for hepatic encephalopathy</article-title><source>Cochrane Database Syst. Rev.</source><year>2004</year><volume>18</volume><pub-id pub-id-type="doi">10.1002/14651858.CD003047.pub2</pub-id></element-citation></ref><ref id="B66-nutrients-10-00329"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>M.R.</given-names></name><name><surname>Chenet</surname><given-names>A.L.</given-names></name><name><surname>Duarte</surname><given-names>A.R.</given-names></name><name><surname>Scaini</surname><given-names>G.</given-names></name><name><surname>Quevedo</surname><given-names>J.</given-names></name></person-group><article-title>Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: A Review</article-title><source>Mol. Neurobiol.</source><year>2017</year><volume>55</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s12035-017-0680-6</pub-id><pub-id pub-id-type="pmid">28695536</pub-id></element-citation></ref><ref id="B67-nutrients-10-00329"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>You</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Barish</surname><given-names>P.A.</given-names></name><name><surname>Vernon</surname><given-names>M.M.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antidepressant-like effect of trans-resveratrol: Involvement of serotonin and noradrenaline system</article-title><source>Eur. Neuropsychopharmacol.</source><year>2010</year><volume>20</volume><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2010.02.013</pub-id><pub-id pub-id-type="pmid">20353885</pub-id></element-citation></ref><ref id="B68-nutrients-10-00329"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.-F.</given-names></name><name><surname>Zhou</surname><given-names>W.H.</given-names></name><name><surname>Cui</surname><given-names>W.-G.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Chronic resveratrol treatment exerts antihyperalgesic effect and corrects co-morbid depressive like behaviors in mice with mononeuropathy: Involvement of serotonergic system</article-title><source>Neuropharmacology</source><year>2014</year><volume>85</volume><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.04.021</pub-id><pub-id pub-id-type="pmid">24835468</pub-id></element-citation></ref><ref id="B69-nutrients-10-00329"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawaz</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Deng</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Shu</surname><given-names>X.</given-names></name></person-group><article-title>Therapeutic Versatility of Resveratrol Derivatives</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><elocation-id>1188</elocation-id><pub-id pub-id-type="doi">10.3390/nu9111188</pub-id><pub-id pub-id-type="pmid">29109374</pub-id></element-citation></ref><ref id="B70-nutrients-10-00329"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosso</surname><given-names>G.</given-names></name><name><surname>Godos</surname><given-names>J.</given-names></name><name><surname>Lamuela-Raventos</surname><given-names>R.</given-names></name><name><surname>Ray</surname><given-names>S.</given-names></name><name><surname>Micek</surname><given-names>A.</given-names></name><name><surname>Pajak</surname><given-names>A.</given-names></name><name><surname>Sciacca</surname><given-names>S.</given-names></name><name><surname>D&#x02019;orazio</surname><given-names>N.</given-names></name><name><surname>Del Rio</surname><given-names>D.</given-names></name><name><surname>Galvano</surname><given-names>F.</given-names></name></person-group><article-title>A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: Level of evidence and limitations</article-title><source>Mol. Nutr. Food Res.</source><year>2017</year><volume>61</volume><pub-id pub-id-type="doi">10.1002/mnfr.201600930</pub-id><pub-id pub-id-type="pmid">27943649</pub-id></element-citation></ref><ref id="B71-nutrients-10-00329"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>M.</given-names></name></person-group><article-title>Acetyl-<sc>l</sc>-carnitine in hepatic encephalopathy</article-title><source>Metab. Brain Dis.</source><year>2013</year><volume>28</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s11011-013-9376-4</pub-id><pub-id pub-id-type="pmid">23389620</pub-id></element-citation></ref><ref id="B72-nutrients-10-00329"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>G.</given-names></name><name><surname>Bertino</surname><given-names>G.</given-names></name><name><surname>Chisari</surname><given-names>G.</given-names></name><name><surname>Motta</surname><given-names>M.</given-names></name><name><surname>Vecchio</surname><given-names>M.</given-names></name><name><surname>Vacante</surname><given-names>M.</given-names></name><name><surname>Caraci</surname><given-names>F.</given-names></name><name><surname>Greco</surname><given-names>C.</given-names></name><name><surname>Drago</surname><given-names>F.</given-names></name><name><surname>Nunnari</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Silybin supplementation during HCV therapy with pegylated interferon-&#x003b1; plus ribavirin reduces depression and anxiety and increases work ability</article-title><source>BMC Psychiatry</source><year>2016</year><volume>16</volume><elocation-id>398</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-016-1115-z</pub-id><pub-id pub-id-type="pmid">27842532</pub-id></element-citation></ref><ref id="B73-nutrients-10-00329"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>M.</given-names></name><name><surname>Bella</surname><given-names>R.</given-names></name><name><surname>Vacante</surname><given-names>M.</given-names></name><name><surname>Giordano</surname><given-names>M.</given-names></name><name><surname>Malaguarnera</surname><given-names>G.</given-names></name><name><surname>Gargante</surname><given-names>M.P.</given-names></name><name><surname>Motta</surname><given-names>M.</given-names></name><name><surname>Mistretta</surname><given-names>A.</given-names></name><name><surname>Rampello</surname><given-names>L.</given-names></name><name><surname>Pennisi</surname><given-names>G.</given-names></name></person-group><article-title>Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy</article-title><source>Scand. J. Gastroenterol.</source><year>2011</year><volume>46</volume><fpage>750</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.3109/00365521.2011.565067</pub-id><pub-id pub-id-type="pmid">21443422</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="nutrients-10-00329-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study design. MHE = Minimal Hepatic Encephalopathy; RV=Resveratrol.</p></caption><graphic xlink:href="nutrients-10-00329-g001"/></fig><fig id="nutrients-10-00329-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Comparison of health related quality of life (HRQL), Depression, and Anxiety. Group A = Resveratrol Group; Group B = Placebo Group; STAI = State-Trait Anxiety Inventory.</p></caption><graphic xlink:href="nutrients-10-00329-g002"/></fig><table-wrap id="nutrients-10-00329-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00329-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Resveratrol Group 35 pt</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Placebo Group 35 pt</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male/Female</td><td align="center" valign="middle" rowspan="1" colspan="1">25/10</td><td align="center" valign="middle" rowspan="1" colspan="1">23/12</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">39&#x02013;60</td><td align="center" valign="middle" rowspan="1" colspan="1">35&#x02013;60</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">144.00 &#x000b1; 18.20</td><td align="center" valign="middle" rowspan="1" colspan="1">145.00 &#x000b1; 19.10</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">82.10 &#x000b1; 10.40</td><td align="center" valign="middle" rowspan="1" colspan="1">81.80 &#x000b1; 10.50</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Heart Rate (bpm)</td><td align="center" valign="middle" rowspan="1" colspan="1">77 &#x000b1; 8</td><td align="center" valign="middle" rowspan="1" colspan="1">75 &#x000b1; 9</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">25.80 &#x000b1; 2.40</td><td align="center" valign="middle" rowspan="1" colspan="1">26.10 &#x000b1; 2.70</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smokers/No Smokers</td><td align="center" valign="middle" rowspan="1" colspan="1">15/20</td><td align="center" valign="middle" rowspan="1" colspan="1">14/21</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cirrhosis etiology</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Post Hepatitis B</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Post Hepatitis C</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Alcoholism</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Child-Pugh Class</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Grade A</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Grade B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S</td></tr></tbody></table><table-wrap-foot><fn><p>SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; BMI: body mass index; N.S = not significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-10-00329-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00329-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparison of clinical parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Characteristics</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Resveratrol Group 35</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Placebo Group 35</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">After RV&#x02192;Placebo</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Urea</td><td align="center" valign="middle" rowspan="1" colspan="1">51.80 &#x000b1; 6.10</td><td align="center" valign="middle" rowspan="1" colspan="1">48.20 &#x000b1; 6.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">51.40 &#x000b1; 5.90</td><td align="center" valign="middle" rowspan="1" colspan="1">50.20 &#x000b1; 6.10</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ammonia</td><td align="center" valign="middle" rowspan="1" colspan="1">66.20 &#x000b1; 7.80</td><td align="center" valign="middle" rowspan="1" colspan="1">41.40 &#x000b1; 6.80</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">62.80 &#x000b1; 7.40</td><td align="center" valign="middle" rowspan="1" colspan="1">59.70 &#x000b1; 6.70</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AST</td><td align="center" valign="middle" rowspan="1" colspan="1">87.80 &#x000b1; 10.70</td><td align="center" valign="middle" rowspan="1" colspan="1">40.40 &#x000b1; 9.80</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">80.40 &#x000b1; 9.80</td><td align="center" valign="middle" rowspan="1" colspan="1">75.20 &#x000b1; 8.70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALT</td><td align="center" valign="middle" rowspan="1" colspan="1">96.40 &#x000b1; 11.80</td><td align="center" valign="middle" rowspan="1" colspan="1">78.40 &#x000b1; 8.70</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">91.70 &#x000b1; 10.20</td><td align="center" valign="middle" rowspan="1" colspan="1">84.20 &#x000b1; 10.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b3;-GT</td><td align="center" valign="middle" rowspan="1" colspan="1">46.10 &#x000b1; 6.70</td><td align="center" valign="middle" rowspan="1" colspan="1">40.40 &#x000b1; 6.40</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">40.80 &#x000b1; 6.40</td><td align="center" valign="middle" rowspan="1" colspan="1">40.50 &#x000b1; 6.10</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Prothrombine time</td><td align="center" valign="middle" rowspan="1" colspan="1">15.40 &#x000b1; 1.80</td><td align="center" valign="middle" rowspan="1" colspan="1">15.00 &#x000b1; 1.20</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">15.50 &#x000b1; 1.70</td><td align="center" valign="middle" rowspan="1" colspan="1">15.10 &#x000b1; 1.60</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bilirubin</td><td align="center" valign="middle" rowspan="1" colspan="1">2.00 &#x000b1; 0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">2.10 &#x000b1; 0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">2.10 &#x000b1; 0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">2.00 &#x000b1; 0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.50 &#x000b1; 0.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.70 &#x000b1; 0.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.60 &#x000b1; 0.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.60 &#x000b1; 0.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S</td></tr></tbody></table><table-wrap-foot><fn><p>AST = Aspartate aminotranferase; ALT = alanine aminotransferase; &#x003b3;-GT = gamma-glutamyl transpeptidase; RV = Resveratrol; N.S = not significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-10-00329-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00329-t003_Table 3</object-id><label>Table 3</label><caption><p>Comparison of HRQL, Depression, and Anxiety.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Characteristics</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Resveratrol Group</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>p</italic></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Placebo Group</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>p</italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">After treatment RV vs. Placebo</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Physical function</td><td align="center" valign="middle" rowspan="1" colspan="1">60.20 &#x000b1; 7.90</td><td align="center" valign="middle" rowspan="1" colspan="1">72.40 &#x000b1; 8.10</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">60.10 &#x000b1; 7.00</td><td align="center" valign="middle" rowspan="1" colspan="1">61.80 &#x000b1; 7.20</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Role physical</td><td align="center" valign="middle" rowspan="1" colspan="1">67.40 &#x000b1; 9.10</td><td align="center" valign="middle" rowspan="1" colspan="1">71.80 &#x000b1; 8.40</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">64.20 &#x000b1; 8.90</td><td align="center" valign="middle" rowspan="1" colspan="1">67.10 &#x000b1; 8.70</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Body pain</td><td align="center" valign="middle" rowspan="1" colspan="1">60.20 &#x000b1; 7.80</td><td align="center" valign="middle" rowspan="1" colspan="1">66.40 &#x000b1; 7.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">60.80 &#x000b1; 7.90</td><td align="center" valign="middle" rowspan="1" colspan="1">62.40 &#x000b1; 7.50</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">General health</td><td align="center" valign="middle" rowspan="1" colspan="1">55.10 &#x000b1; 7.20</td><td align="center" valign="middle" rowspan="1" colspan="1">65.80 &#x000b1; 6.80</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">57.20 &#x000b1; 7.30</td><td align="center" valign="middle" rowspan="1" colspan="1">59.20 &#x000b1; 7.50</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vitality</td><td align="center" valign="middle" rowspan="1" colspan="1">59.20 &#x000b1; 6.20</td><td align="center" valign="middle" rowspan="1" colspan="1">64.00 &#x000b1; 6.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">61.80 &#x000b1; 6.50</td><td align="center" valign="middle" rowspan="1" colspan="1">60.70 &#x000b1; 6.70</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Role emotional</td><td align="center" valign="middle" rowspan="1" colspan="1">61.70 &#x000b1; 7.70</td><td align="center" valign="middle" rowspan="1" colspan="1">65.20 &#x000b1; 7.40</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">61.90 &#x000b1; 7.40</td><td align="center" valign="middle" rowspan="1" colspan="1">62.80 &#x000b1; 7.20</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mental health</td><td align="center" valign="middle" rowspan="1" colspan="1">58.70 &#x000b1; 8.70</td><td align="center" valign="middle" rowspan="1" colspan="1">64.80 &#x000b1; 7.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">62.40 &#x000b1; 7.70</td><td align="center" valign="middle" rowspan="1" colspan="1">62.40 &#x000b1; 7.40</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Social function</td><td align="center" valign="middle" rowspan="1" colspan="1">60.20 &#x000b1; 7.10</td><td align="center" valign="middle" rowspan="1" colspan="1">69.80 &#x000b1; 7.50</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">61.40 &#x000b1; 7.50</td><td align="center" valign="middle" rowspan="1" colspan="1">62.70 &#x000b1; 7.70</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Beck Depression Inventory</td><td align="center" valign="middle" rowspan="1" colspan="1">28.10 &#x000b1; 3.40</td><td align="center" valign="middle" rowspan="1" colspan="1">20.40 &#x000b1; 3.20</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">27.80 &#x000b1; 3.50</td><td align="center" valign="middle" rowspan="1" colspan="1">26.40 &#x000b1; 3.20</td><td align="center" valign="middle" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.40 &#x000b1; 7.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.80 &#x000b1; 6.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.90 &#x000b1; 7.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.80 &#x000b1; 7.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></table-wrap></floats-group></article>